Diagnostics of hemostasiological indicators of blood in patients with cervical cancer: standards, innovative models of the future (Ukraine)
DOI:
https://doi.org/10.57125/FEM.2022.12.30.01Keywords:
cervical cancer, hemostasiological indicators, blood diagnostics, standards, innovative models, UkraineAbstract
This article focused on “Diagnostics of hemostasiological indicators of blood in patients with cervical cancer: standards, innovative models of the future (Ukraine)”.
Aims: The aims of this study are to investigate the current standards, the innovative models, prognostic and predictive value of hemostasiological indicators of blood in patients with cervical cancer and identifications of potential gaps and opportunities in the current standards and innovative models for hemostasiological assessment.
Methodology: A descriptive cross-sectional study design was evaluated. Secondary data were collected. Descriptive statistics were obtained and utilised.
Results: The result showed that in 2020, Ukraine had 20.3 new cervical cancer cases per 100,000 women, regardless of age. Age-standardised cervical cancer incidence was 14.3 per 100,000 women. In 2020, Ukraine's lifetime cervical cancer risk was 1.4%. It illustrates cervical cancer risk. Prothrombin Time is 11–14 seconds, Activated Partial Thromboplastin Time is 25–35 seconds, fibrinogen is 200–400 mg/dL, and platelet counts are 150,000–450,000/L. Thromboelastography is a viscoelastic test that dynamically assesses blood clot formation, strength, and lysis. This test helps doctors assess cervical cancer patients' haemostatic profile and thrombotic risk and establish thromboprophylaxis regimens. In advanced cervical cancer patients, prothrombin time, APTT, fibrinogen, D-dimer, and platelet count predict thrombotic events and poor prognosis. These signs extend VTE risk. Potential gaps or opportunities include a lack of established practices, few complicated hemostasiological tests, little research, lack of knowledge and teaching, and difficulties with monitoring and follow-up, especially in resource-poor areas. Standardising techniques, expanding access to cutting-edge hemostasiological tests, and remote monitoring, and running education and awareness campaigns are future potentials for research and development.
Scientific Novelty: cutting-edge hemostasiological tests in cervical cancer.
Conclusion: In conclusion, resolving global cervical cancer mortality disparities needs healthcare, cancer prevention, screening, awareness, socioeconomic variables, and creative hemostasiological evaluation models. Better care, thromboprophylaxis, and collaboration can improve cervical cancer outcomes worldwide.
References
Buskwofie A, David-West G, Clare CA. A Review of Cervical Cancer: Incidence and Disparities. J Natl Med Assoc 2020;112:229–32. https://doi.org/10.1016/J.JNMA.2020.03.002.
Tseng JH, Aloisi A, Sonoda Y, Gardner GJ, Zivanovic O, Abu-Rustum NR, Leitao MM Jr. Less versus more radical surgery in stage IB1 cervical cancer: A population-based study of long-term survival. Gynecol Oncol. 2018 Jul;150(1):44-49. doi: 10.1016/j.ygyno.2018.04.571.
Fontham ETH, Wolf AMD, Church TR, Etzioni R, Flowers CR, Herzig A, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin 2020;70:321–46. https://doi.org/10.3322/CAAC.21628.
Saslow D, Andrews KS, Manassaram‐Baptiste D, Smith RA, Fontham ETH. Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation. CA Cancer J Clin 2020;70:274–80. https://doi.org/10.3322/CAAC.21616.
Hu Z, Ma D. The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. Cancer Med 2018;7:5217–36. https://doi.org/10.1002/CAM4.1501.
Comprehensive cervical cancer prevention and control: a healthier future for girls and women [Internet]. Who.int. [cited 2021 May 1]. Available from: https://apps.who.int/iris/bitstream/handle/10665/78128/9789241505147_eng.pdf;jsessionid=5CA2DE1EE75660AE53921E42B35D0B73?sequence=3
Wilailak S, Kengsakul M, Kehoe S. Worldwide initiatives to eliminate cervical cancer. Int J Gynaecol Obstet [Internet]. 2021;155(S1):102–6. Available from: http://dx.doi.org/10.1002/ijgo.13879
Shi D, Liang Z, Zhang C, Zhang H, Liu X. The effect of surgery on the survival status of patients with locally advanced cervical cancer after radiotherapy/chemoradiotherapy: a meta-analysis. BMC Cancer [Internet]. 2018;18(1). Available from: http://dx.doi.org/10.1186/s12885-018-4232-x
Zeng J, Sun P, Ping Q, Jiang S, Hu Y. Clinical outcome of FIGO 2018 stage IB3/IIA2 cervical cancer treated by neoadjuvant chemotherapy followed by radical surgery due to lack of radiotherapy equipment: A retrospective comparison with concurrent chemoradiotherapy. PLoS One [Internet]. 2022;17(3):e0266001. Available from: http://dx.doi.org/10.1371/journal.pone.0266001
Salib MY, Russell JHB, Stewart VR, Sudderuddin SA, Barwick TD, Rockall AG, et al. 2018 FIGO staging classification for cervical cancer: Added benefits of imaging. Radiographics [Internet]. 2020;40(6):1807–22. Available from: http://dx.doi.org/10.1148/rg.2020200013
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin [Internet]. 2021;71(3):209–49. Available from: http://dx.doi.org/10.3322/caac.21660
Ding Y, Zhang X, Qiu J, Zhang J, Hua K. Assessment of ESGO quality indicators in cervical cancer surgery: A real-world study in a high-volume Chinese hospital. Front Oncol [Internet]. 2022;12. Available from: http://dx.doi.org/10.3389/fonc.2022.802433
Tapera O, Dreyer G, Kadzatsa W, Nyakabau AM, Stray-Pedersen B, Sjh H. Cervical cancer knowledge, attitudes, beliefs and practices of women aged at least 25 years in Harare, Zimbabwe. BMC Womens Health [Internet]. 2019;19(1):91. Available from: http://dx.doi.org/10.1186/s12905-019-0790-6
Khargekar N, Khanna D, Budukh A. Knowledge, attitude, and practice about cervical cancer and its screening among community healthcare workers of Varanasi district, Uttar Pradesh, India. J Family Med Prim Care [Internet]. 2019;8(5):1715. Available from: http://dx.doi.org/10.4103/jfmpc.jfmpc_143_19
Shibata K, Tokushige A, Imamura M, Ikeda Y, Ohishi M. Evaluating the Khorana risk score of gastrointestinal cancer patients during initial chemotherapy as a predictor of patient mortality: A retrospective study. J Cardiol [Internet]. 2022;79(5):655–63. Available from: http://dx.doi.org/10.1016/j.jjcc.2021.11.024
Yuk J-S, Lee B, Kim MH, Kim K, Seo Y-S, Hwang SO, et al. Incidence and risk factors of VTE in patients with cervical cancer using the Korean national health insurance data. Sci Rep [Internet]. 2021;11(1):8031. Available from: http://dx.doi.org/10.1038/s41598-021-87606-z
Amgalan A, Allen T, Othman M, Ahmadzia HK. Systematic review of viscoelastic testing (TEG/ROTEM) in obstetrics and recommendations from the women’s SSC of the ISTH. J Thromb Haemost [Internet]. 2020;18(8):1813–38. Available from: http://dx.doi.org/10.1111/jth.14882
Walsh M, Moore EE, Moore H, Thomas S, Lune SV, Zimmer D, et al. Use of viscoelastography in malignancy-associated coagulopathy and thrombosis: A review. Semin Thromb Hemost [Internet]. 2019;45(4):354–72. Available from: http://dx.doi.org/10.1055/s-0039-1688497
Monaghan TF, Rahman SN, Agudelo CW, Wein AJ, Lazar JM, Everaert K, et al. Foundational statistical principles in medical research: Sensitivity, specificity, positive predictive value, and negative predictive value. Medicina (Kaunas) [Internet]. 2021;57(5):503. Available from: http://dx.doi.org/10.3390/medicina57050503
Rynhach NO, Kuryk OG, Hryhorchuk SP, Dumytska IV, Bazdyriev KV, Myrvoda SS, et al. Analysis of the achievement of the global purpose of elimination of cervical cancer in Ukraine. World Med Biol [Internet]. 2022;18(81):142. Available from: http://dx.doi.org/10.26724/2079-8334-2022-3-81-142-147
Canfell K, Kim JJ, Brisson M, Keane A, Simms KT, Caruana M, et al. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet [Internet]. 2020;395(10224):591–603. Available from: http://dx.doi.org/10.1016/s0140-6736(20)30157-4
Yang W, Hosgood G, Luobikis K, Paul A. Agreement of point-of-care prothrombin and activated partial thromboplastin time in dogs with a reference laboratory. Aust Vet J [Internet]. 2018;96(10):379–84. Available from: http://dx.doi.org/10.1111/avj.12746
Yuk J-S, Lee B, Kim MH, Kim K, Seo Y-S, Hwang SO, et al. Incidence and risk factors of VTE in patients with cervical cancer using the Korean national health insurance data. Sci Rep [Internet]. 2021;11(1):8031. Available from: http://dx.doi.org/10.1038/s41598-021-87606-z
Li B, Shou Y, Zhu H. Predictive value of hemoglobin, platelets, and D-dimer for the survival of patients with stage IA1 to IIA2 cervical cancer: a retrospective study. J Int Med Res [Internet]. 2021;49(12):3000605211061008. Available from: http://dx.doi.org/10.1177/03000605211061008
Laskov I, Grisaru D, Deutsch V, Fargo N, Raz Y, Mishaan N. Evaluation of the hypercoagulable state of gynecologic cancer patients by thromboelastography: a prospective pilot study and a review of the literature. Eur J Gynaecol Oncol [Internet]. 2019;40(6):988–93. Available from: http://dx.doi.org/10.12892/ejgo5003.2019
Walsh M, Moore EE, Moore H, Thomas S, Lune SV, Zimmer D, et al. Use of viscoelastography in malignancy-associated coagulopathy and thrombosis: A review. Semin Thromb Hemost [Internet]. 2019;45(4):354–72. Available from: http://dx.doi.org/10.1055/s-0039-1688497
Programmes STI. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention [Internet]. Who.int. World Health Organization; 2021 [cited 2021 May 1]. Available from: https://www.who.int/publications/i/item/9789240030824
Walsh M, Moore EE, Moore H, Thomas S, Lune SV, Zimmer D, et al. Use of viscoelastography in malignancy-associated coagulopathy and thrombosis: A review. Semin Thromb Hemost [Internet]. 2019;45(4):354–72. Available from: http://dx.doi.org/10.1055/s-0039-1688497
Selby R. “TEG talk”: expanding clinical roles for thromboelastography and rotational thromboelastometry. Hematology Am Soc Hematol Educ Program [Internet]. 2020;2020(1):67–75. Available from: http://dx.doi.org/10.1182/hematology.2020000090
Onyango CG, Ogonda L, Guyah B, Shiluli C, Ganda G, Orang’o OE, et al. Novel biomarkers with promising benefits for diagnosis of cervical neoplasia: a systematic review. Infect Agent Cancer [Internet]. 2020;15(1):68. Available from: http://dx.doi.org/10.1186/s13027-020-00335-2
Lim HY, O’Malley C, Donnan G, Nandurkar H, Ho P. A review of global coagulation assays - Is there a role in thrombosis risk prediction? Thromb Res [Internet]. 2019;179:45–55. Available from: http://dx.doi.org/10.1016/j.thromres.2019.04.033
Zhang L, Ye J, Luo Q, Kuang M, Mao M, Dai S, et al. Prediction of poor outcomes in patients with colorectal cancer: Elevated preoperative prothrombin time (PT) and activated partial thromboplastin time (APTT). Cancer Manag Res [Internet]. 2020;12:5373–84. Available from: http://dx.doi.org/10.2147/CMAR.S246695
Bian Z, Meng J, Niu Q, Jin X, Wang J, Feng X, et al. Prognostic role of prothrombin time activity, prothrombin time, albumin/globulin ratio, platelets, sex, and fibrinogen in predicting recurrence-free survival time of renal cancer. Cancer Manag Res [Internet]. 2020;12:8481–90. Available from: http://dx.doi.org/10.2147/CMAR.S264856
Xie L, Chu R, Wang K, Zhang X, Li J, Zhao Z, et al. Prognostic assessment of cervical cancer patients by clinical staging and surgical-pathological factor: A support vector machine-based approach. Front Oncol [Internet]. 2020;10:1353. Available from: http://dx.doi.org/10.3389/fonc.2020.01353
Hu X, Liu H, Ye M, Zhu X. Prognostic value of microvessel density in cervical cancer. Cancer Cell Int [Internet]. 2018;18(1):152. Available from: http://dx.doi.org/10.1186/s12935-018-0647-3
Noh JJ, Lim MC, Kim M-H, Kim YH, Song ES, Seong SJ, et al. The prognostic model of pre-treatment complete blood count (CBC) for recurrence in early cervical cancer. J Clin Med [Internet]. 2020;9(9):2960. Available from: http://dx.doi.org/10.3390/jcm9092960
Posters abstracts. Res Pract Thromb Haemost [Internet]. 2020;4(S1):1–1311. Available from: http://dx.doi.org/10.1002/rth2.12393
World Bank. Cervical cancer in Ukraine: The continuum of care and implications for action. World Bank, Washington, DC; 2019. Available from: https://doi.org/10.1596/31156.
Lin S, Gao K, Gu S, You L, Qian S, Tang M, et al. Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years. Cancer [Internet]. 2021;127(21):4030–9. Available from: http://dx.doi.org/10.1002/cncr.33795
Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond) [Internet]. 2021;41(10):1037–48. Available from: http://dx.doi.org/10.1002/cac2.12197
Dorgalaleh A, Favaloro EJ, Bahraini M, Rad F. Standardization of prothrombin time/international normalized ratio (PT/INR). Int J Lab Hematol [Internet]. 2021;43(1):21–8. Available from: http://dx.doi.org/10.1111/ijlh.13349
Noh JJ, Lim MC, Kim M-H, Kim YH, Song ES, Seong SJ, et al. The prognostic model of pre-treatment complete blood count (CBC) for recurrence in early cervical cancer. J Clin Med [Internet]. 2020;9(9):2960. Available from: http://dx.doi.org/10.3390/jcm9092960
Khichariya G, K M, Das S, R K. A study of coagulation profile in patients with cancer in a tertiary care hospital. J Hematol Clin Res [Internet]. 2021;5(1):001–3. Available from: http://dx.doi.org/10.29328/journal.jhcr.1001015
Amin R, Kolahi A-A, Jahanmehr N, Abadi A-R, Sohrabi M-R. Disparities in cervical cancer screening participation in Iran: a cross-sectional analysis of the 2016 nationwide STEPS survey. BMC Public Health [Internet]. 2020;20(1):1594. Available from: http://dx.doi.org/10.1186/s12889-020-09705-2
World Bank. Cervical cancer in Ukraine: The continuum of care and implications for action. World Bank, Washington, DC; 2019. Available from: https://doi.org/10.1596/31156.
World Health Organization (Who). Comprehensive cervical cancer control: A guide to essential practice [Internet]. World Health Organization; 2014 [cited 2021 May 1]. Available from: https://www.who.int/publications/i/item/9789241548953
Arbyn M, Gultekin M, Morice P, Nieminen P, Cruickshank M, Poortmans P, et al. The European response to the WHO call to eliminate cervical cancer as a public health problem. Int J Cancer [Internet]. 2021;148(2):277–84. Available from: http://dx.doi.org/10.1002/ijc.33189
Pengo V, Prandoni P. Abstracts of the 25th biennial international congress on thrombosis. In: The 25th Biennial International Congress on Thrombosis. Basel Switzerland: MDPI; 2018. p. 531. Available from: https://doi.org/10.3390/PROCEEDINGS2090531.
Gatumo M, Gacheri S, Sayed A-R, Scheibe A. Women’s knowledge and attitudes related to cervical cancer and cervical cancer screening in Isiolo and Tharaka Nithi counties, Kenya: a cross-sectional study. BMC Cancer [Internet]. 2018;18(1). Available from: http://dx.doi.org/10.1186/s12885-018-4642-9
Shiferaw S, Addissie A, Gizaw M, Hirpa S, Ayele W, Getachew S, et al. Knowledge about cervical cancer and barriers toward cervical cancer screening among HIV-positive women attending public health centers in Addis Ababa city, Ethiopia. Cancer Med [Internet]. 2018;7(3):903–12. Available from: http://dx.doi.org/10.1002/cam4.1334
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 author
This work is licensed under a Creative Commons Attribution 4.0 International License.
